Gemini Bioproducts, LLC Expands Product Lines with New Acquisition from Bio-Techne

Gemini Bioproducts, LLC, widely recognized as a prominent provider of cell culture reagents, has taken a significant step forward by acquiring selected product rights and inventory pertaining to fetal bovine serum (FBS) from Bio-Techne. This strategic acquisition represents a critical enhancement in their offerings and aims to solidify customer support in terms of quality and supply chain integrity.

Established in 1985, GeminiBio boasts a long history of servicing clients within the biotechnology sector, particularly in the realm of FBS, over the last 39 years. This extensive experience has equipped the company with the skills necessary to manage and meet the demands of life sciences, participating actively in ensuring continuous product availability. Following Bio-Techne's recent announcement to discontinue their FBS product line—including renowned brands such as Optima, Premium Select, and Premium—GeminiBio collaborated closely with the organization to ensure that an effective transition plan is in place.

Will Geist, the President of Bio-Techne's Protein Science Segment, stated, "Although Bio-Techne has chosen to discontinue the FBS product line, our efforts have been concentrated on providing a smooth transition. We're pleased that these vital cell culture products will remain accessible through GeminiBio." This commitment emphasizes the trust that Bio-Techne has put in GeminiBio, acknowledging their stringent cGMP manufacturing capabilities and overall product quality.

Moreover, Brian Parker, the CEO of GeminiBio, expressed enthusiasm about this development. "Our dedication to maintaining market access remains steadfast. Customers can expect no less than the same high-quality standards they have come to rely on, along with stable supply chains and product specifications." This acquisition not only consolidates GeminiBio's market position but also offers enhanced options for customers looking for expanded supply chain security.

The effective transfer date for these products to GeminiBio is set for December 3, 2024. Any inquiries or orders regarding Optima, Premium Select, and Premium FBS should be directed to their customer service team starting on that date.

GeminiBio has enhanced its manufacturing capabilities over the past two years, opening two dedicated facilities in West Sacramento, California. One facility caters to animal-origin products while the other focuses on animal-origin-free solutions, highlighting their versatility in addressing various client needs. The expansion of these cGMP-compliant facilities not only amplifies their production capacity but also enhances their service capabilities to a diverse array of clients in the life sciences field, including startup researchers and established commercial biotech companies.

Through this acquisition, GeminiBio is poised to amplify its growth trajectory significantly. Parker noted, "We are excited to integrate these new product brands and offer continued support to our new customers. This acquisition also expands our operational capacity and scale, fostering our mission of aiding customers in accelerating the development of impactful biotherapeutics."

About BelHealth Investment Partners

BelHealth Investment Partners, a Florida-based private equity firm, specializes in healthcare investments, particularly in lower middle-market companies. They bring a unique mix of industry experience and resources, aiming to enhance entrepreneur-owned companies with their comprehensive operational and investment strategies. Their current investment drive is through a $350 million fund.

About GeminiBio

Located in West Sacramento, California, GeminiBio supports the global biotechnology industry, focusing on the transition from basic research to commercial production. Serving diverse customer segments with a dual focus on Cell Culture Solutions and Process Liquid Solutions, the company remains committed to facilitating the development of biotherapeutics.

For further inquiries related to this acquisition or product offerings, interested parties are encouraged to reach out to GeminiBio directly or visit their website at www.geminibio.com.